nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

12.08.2016 | Original Article – Cancer Research

DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer

verfasst von: Tianbo Gao, Min Wang, Lingling Xu, Tao Wen, Jian Liu, Guangyu An

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Metastasis is a primary cause of colorectal cancer (CRC)-related death, and cancer stem cells (CSCs) are thought to be majorly responsible for initiating metastatic behaviors. Doublecortin-like kinase 1 (DCLK1) was recently discovered to be a marker for gastrointestinal CSCs. Here, we aimed to explore whether DCLK1 is associated with CRC metastasis through clinical and in vitro investigations.

Methods

The expression levels of DCLK1 mRNA and protein in human CRC tissues were analyzed through quantitative RT-PCR and immunohistochemistry staining, respectively. Human CRC cell line SW480 was selected to explore the effect of DCLK1 overexpression on cell migration and invasion. Besides, the associations between DCLK1 and epithelial–mesenchymal transition (EMT) were determined.

Results

Compared to normal colorectal tissues, DCLK1 expression was significantly up-regulated in human CRC tissues and correlated well with high lymphatic metastasis and poor prognosis in patients. DCLK1 expression was inversely associated with overall survival in CRC patients. Overexpression of DCLK1 in SW480 cells markedly promoted cell migration and invasion. Furthermore, we validated that DCLK1 could facilitate EMT in cancer cells by up-regulation of the mesenchymal markers Vimentin and ZEB1 and down-regulation of the epithelial marker E-cadherin in SW480 cells.

Conclusions

DCLK1 up-regulation may play a contributory role in CRC metastasis and poor prognosis via activation of EMT. DCLK1 may serve as an independent predictor for CRC prognosis.

Cerami E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. doi:10.1158/2159-8290.cd-12-0095 CrossRefPubMed

Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science (New York, NY) 331:1559–1564. doi:10.1126/science.1203543 CrossRef

Christofori G (2006) New signals from the invasive front. Nature 441:444–450. doi:10.1038/nature04872 CrossRefPubMed

Gagliardi G, Moroz K, Bellows CF (2012) Immunolocalization of DCAMKL-1, a putative intestinal stem cell marker, in normal colonic tissue. Pathol Res Pract 208:475–479. doi:10.1016/j.prp.2012.05.015 CrossRefPubMed

Gao J et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1. doi:10.1126/scisignal.2004088 CrossRefPubMedPubMedCentral

Kantara C, O’Connell MR, Luthra G, Gajjar A, Sarkar S, Ullrich RL, Singh P (2015) Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasis. Lab Investig 95:100–112. doi:10.1038/labinvest.2014.133 CrossRefPubMed

Li L, Bellows CF (2013) Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line Chin. J Cancer Res 25:134–142. doi:10.3978/j.issn.1000-9604.2013.03.02

Liang X (2011) EMT: new signals from the invasive front. Oral Oncol 47:686–687. doi:10.1016/j.oraloncology.2011.04.016 CrossRefPubMed

Lin PT, Gleeson JG, Corbo JC, Flanagan L, Walsh CA (2000) DCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerization. J Neurosci 20:9152–9161PubMed

May R et al (2009) Doublecortin and CaM kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells 27:2571–2579. doi:10.1002/stem.193 CrossRefPubMedPubMedCentral

Mirzaei A et al (2015a) Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients. Tumour Biol J Int Soc Oncodev Biol Med 36:4801–4810. doi:10.1007/s13277-015-3132-9 CrossRef

Mirzaei A et al (2015b) A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer? Tumour Biol J Int Soc Oncodev Biol Med. doi:10.1007/s13277-015-3989-7

Mitra A, Mishra L, Li S (2015) EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6:10697–10711. doi:10.18632/oncotarget.4037 CrossRefPubMedPubMedCentral

Nakanishi Y et al (2013) Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet 45:98–103. doi:10.1038/ng.2481 CrossRefPubMed

O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425. doi:10.1093/jnci/djh275 CrossRefPubMed

Qu D et al (2015) Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. PLoS One 10:e0118933. doi:10.1371/journal.pone.0118933 CrossRefPubMedPubMedCentral

Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, Kuipers EJ (2015) Colorectal cancer screening: a global overview of existing programmes. Gut 64:1637–1649. doi:10.1136/gutjnl-2014-309086 CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 5016. CA Cancer J Clin 66:7–30. doi:10.3322/caac.21332 CrossRefPubMed

Soini Y et al (2011) Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer 11:73. doi:10.1186/1471-2407-11-73 CrossRefPubMedPubMedCentral

Stein U, Schlag PM (2007) Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 176:61–80CrossRefPubMed

Sureban SM et al (2011) Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotech 9:40. doi:10.1186/1477-3155-9-40 CrossRef

Sureban SM et al (2014) XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett 351:151–161. doi:10.1016/j.canlet.2014.05.011 CrossRefPubMed

Sureban SM et al (2015) Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism. Oncotarget 6:37200–37215. doi:10.18632/oncotarget.5808 PubMedPubMedCentral

Tsai JH, Yang J (2013) Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 27:2192–2206. doi:10.1101/gad.225334.113 CrossRefPubMedPubMedCentral

Vega KJ et al (2012) Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett’s esophagus and esophageal adenocarcinoma. J Gastroenterol Hepatol 27:773–780. doi:10.1111/j.1440-1746.2011.06928.x CrossRefPubMedPubMedCentral

Weygant N et al (2014) Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer 13:103. doi:10.1186/1476-4598-13-103 CrossRefPubMedPubMedCentral

Titel: DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer
verfasst von: Tianbo Gao
Min Wang
Lingling Xu
Tao Wen
Jian Liu
Guangyu An
Publikationsdatum: 12.08.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-016-2218-0

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2016

Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients

Bone morphogenetic protein signaling in musculoskeletal cancer

Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity

Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification

Robot-assisted surgery versus conventional laparoscopic surgery for endometrial cancer: a systematic review and meta-analysis

Telangiectatic osteosarcoma: a review of 87 cases

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie